Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

mTOR activation in medullary thyroid carcinoma with RAS mutation.

European journal of endocrinology - 1 Nov 2014

Lyra Joana, Vinagre João, Batista Rui, Pinto Vasco, Prazeres Hugo, Rodrigues Fernando, Eloy Catarina, Sobrinho-Simões Manuel, Soares Paula

Abstract excerpt

OBJECTIVE: Rearranged during transfection (RET) mutations are well-known genetic events in sporadic and familial medullary thyroid carcinoma (FMTC). The presence of RAS mutations in sporadic cases, challenging the RET paradigm in these tumors, has been recently reported. We intend to evaluate mTOR pathway activation in RET- and RAS-mutated MTC. MATERIALS AND METHODS: In this study, we analysed the presence of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, ras

Share to Proto-Oncogene Proteins c-ret

Share to Signal Transduction

Share to Thyroid Neoplasms

Share to TOR Serine-Threonine Kinases

Share to Transcriptional Activation

Source

Identifiers

PMID: 25163725
DOI: 10.1530/EJE-14-0389

Genes

RET
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

mTOR activation in medullary thyroid carcinoma with RAS mutation.PMID 25163725Read ↗

Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma.Semantic proximity Read ↗

mTOR Pathway Overactivation in BRAF Mutated Papillary Thyroid CarcinomaSemantic proximity Read ↗

High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.Semantic proximity Read ↗

RAS proto-oncogene in medullary thyroid carcinoma.Semantic proximity Read ↗

Somatic<i>RAS</i>Mutations Occur in a Large Proportion of Sporadic<i>RET</i>-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonSemantic proximity Read ↗

The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study.Semantic proximity Read ↗

The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.Semantic proximity Read ↗

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.Semantic proximity Read ↗

Evidence of a Low Prevalence of <i>RAS</i> Mutations in a Large Medullary Thyroid Cancer SeriesSemantic proximity Read ↗

Functional significance of the novel H-RAS gene mutation M72I in a patient with medullary thyroid cancer.Semantic proximity Read ↗

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.Semantic proximity Read ↗

Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.